The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Renosen Pharmaceuticals Pvt Ltd
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Renosen Pharmaceuticals Pvt Ltd, part of the promoter group of Senores Pharmaceuticals, disclosed an open market purchase of 6,000 equity shares on December 31, 2025 under SEBI SAST Regulation 29(2). Before the acquisition, Renosen held 27,12,719 shares (5.89% of voting capital); after the purchase, its holding rose marginally to 27,18,719 shares (5.90%). The total share capital of the company remains unchanged at 4,60,53,588 equity shares of Rs. 10 each. The change in stake is negligible at just 0.01%, suggesting routine promoter buying rather than a meaningful strategic shift.
This is a very small, incremental purchase by a promoter group entity and is unlikely to materially affect the stock price. It signals continued promoter confidence but does not change the overall promoter holding meaningfully.